Literature DB >> 7692460

CD5 positive B lymphocytes in schizophrenia: no alteration in numbers or percentage as compared with control subjects.

R Ganguli1, B S Rabin.   

Abstract

Some patients with autoimmune disease have an elevation of the B lymphocyte population bearing the CD5 marker. In an attempt to replicate an earlier report of elevated CD5+ B cells in schizophrenic patients, lymphocytes were phenotyped in 116 patients with schizophrenia and 166 control subjects. The CD5+ B lymphocyte population was not elevated in medicated or never-medicated patients as compared with control subjects of similar age, race, gender, or social class. CD5+ B cells were also not elevated in patients who had circulating autoantibodies. The CD5+ B lymphocyte population was significantly elevated in African-American control subjects and patients in comparison with that in Caucasian control subjects and patients. Thus, although other immune alterations characterized a subset of patients with schizophrenia, an elevation of the CD5+ B lymphocyte population was not found in this study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692460     DOI: 10.1016/0165-1781(93)90114-v

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

Review 1.  Viruses, schizophrenia, and bipolar disorder.

Authors:  R H Yolken; E F Torrey
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

2.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

3.  Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity.

Authors:  Johann Steiner; Roland Jacobs; Benjamin Panteli; Mareike Brauner; Kolja Schiltz; Sabine Bahn; Marlis Herberth; Sabine Westphal; Tomasz Gos; Martin Walter; Hans-Gert Bernstein; Aye Mu Myint; Bernhard Bogerts
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-01-27       Impact factor: 5.270

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.